SBIO vs. PBE
Compare and contrast key facts about ALPS Medical Breakthroughs ETF (SBIO) and Invesco Dynamic Biotechnology & Genome ETF (PBE).
SBIO and PBE are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. SBIO is a passively managed fund by SS&C that tracks the performance of the S-Network Medical Breakthroughs Index. It was launched on Dec 31, 2014. PBE is a passively managed fund by Invesco that tracks the performance of the Dynamic Biotech & Genome Intellidex Index (AMEX). It was launched on Jun 23, 2005. Both SBIO and PBE are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: SBIO or PBE.
Correlation
The correlation between SBIO and PBE is 0.87, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
SBIO vs. PBE - Performance Comparison
Key characteristics
SBIO:
0.52
PBE:
0.31
SBIO:
0.91
PBE:
0.56
SBIO:
1.10
PBE:
1.07
SBIO:
0.30
PBE:
0.20
SBIO:
1.68
PBE:
1.34
SBIO:
9.05%
PBE:
4.37%
SBIO:
29.33%
PBE:
18.58%
SBIO:
-63.06%
PBE:
-45.69%
SBIO:
-44.84%
PBE:
-19.74%
Returns By Period
In the year-to-date period, SBIO achieves a 6.29% return, which is significantly higher than PBE's 2.15% return.
SBIO
6.29%
-5.78%
5.08%
13.27%
-3.88%
N/A
PBE
2.15%
-0.62%
3.23%
3.91%
3.57%
3.42%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
SBIO vs. PBE - Expense Ratio Comparison
SBIO has a 0.50% expense ratio, which is lower than PBE's 0.59% expense ratio.
Risk-Adjusted Performance
SBIO vs. PBE - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and Invesco Dynamic Biotechnology & Genome ETF (PBE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
SBIO vs. PBE - Dividend Comparison
SBIO's dividend yield for the trailing twelve months is around 3.47%, more than PBE's 0.05% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
SBIO ALPS Medical Breakthroughs ETF | 3.47% | 0.22% | 0.00% | 0.00% | 0.00% | 0.04% | 2.79% | 1.77% | 0.00% | 0.00% | 0.00% |
PBE Invesco Dynamic Biotechnology & Genome ETF | 0.05% | 0.02% | 0.00% | 0.00% | 0.04% | 0.00% | 0.00% | 0.57% | 0.38% | 1.12% | 0.55% |
Drawdowns
SBIO vs. PBE - Drawdown Comparison
The maximum SBIO drawdown since its inception was -63.06%, which is greater than PBE's maximum drawdown of -45.69%. Use the drawdown chart below to compare losses from any high point for SBIO and PBE. For additional features, visit the drawdowns tool.
Volatility
SBIO vs. PBE - Volatility Comparison
ALPS Medical Breakthroughs ETF (SBIO) has a higher volatility of 9.71% compared to Invesco Dynamic Biotechnology & Genome ETF (PBE) at 5.85%. This indicates that SBIO's price experiences larger fluctuations and is considered to be riskier than PBE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.